Skip to main content

Table 3 Pharmacokinetic properties of meropenem in serum and cerebrospinal fluid

From: Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study

Patient number CL (L/h) Vc (L) t 1/2 (h) AUC0–24 serum (mg∙h/L) AUC0–24 CSF (mg∙h/L) CSF/serum ratio t 1/2cb (h) t 1/2bc (h)
1 7.63 6.45 0.59 768.63 85.53 0.11 3.30 4.62
2 17.88 14.45 0.56 327.09 53.00 0.16 17.33 9.90
3 8.62 14.95 1.20 428.94 48.59 0.11 4.62 3.47
4 20.38 5.05 0.17 300.14 19.37 0.06 13.86 17.33
5 22.87 14.95 0.45 237.60 8.93 0.04 17.33 2.57
6 14.89 5.05 0.24 401.45 18.63 0.05 34.66 69.31
7 23.37 14.95 0.44 258.79 15.02 0.06 34.66 5.78
8 7.88 5.05 0.44 760.20 79.10 0.10 8.66 9.90
9 17.13 14.95 0.60 280.81 26.56 0.09 23.10 17.33
10 11.88 13.75 0.80 489.44 27.25 0.06 69.31 34.66
11 20.63 12.75 0.43 287.15 15.59 0.05 34.66 17.33
12 29.87 9.95 0.23 112.95 10.56 0.09 11.55 9.90
13 15.07 5.05 0.23 234.65 22.10 0.09 23.10 69.31
14 9.63 14.95 1.08 569.59 48.90 0.09 13.86 5.78
15 14.88 5.05 0.24 413.23 25.62 0.06 34.66 69.31
16 17.13 14.95 0.60 337.21 30.99 0.09 23.10 17.33
17 14.98 5.08 0.24 415.22 17.31 0.04 34.66 69.31
18 10.63 5.05 0.33 563.84 42.95 0.08 5.78 8.66
19 13.12 14.95 0.79 394.45 33.99 0.09 34.66 13.86
20 17.13 14.95 0.60 350.22 33.71 0.10 23.10 17.33
21 18.88 14.15 0.52 242.60 7.44 0.03 17.33 1.73
Median 15.07 13.75 0.63 350.22 26.56 0.09 23.10 13.86
Minimum 7.63 5.05 0.17 112.95 7.44 0.03 3.30 1.73
Maximum 29.87 14.95 1.20 768.63 85.53 0.16 69.31 69.31
  1. Abbreviations: CSF Cerebrospinal fluid, CL Median clearance, t 1/2 Median half-life, V c Median volume of distribution of the central compartment, AUC 0–24 Daily average area under the curve, CSF/serum ratio Cerebrospinal fluid penetration, t 1/2cb Median absorption half-life into cerebrospinal fluid, t 1/2bc Median elimination half-life of cerebrospinal fluid
  2. Individual pharmacokinetic results in serum and CSF obtained using Pmetrics